142 related articles for article (PubMed ID: 16402538)
1. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
Scheen AJ; Lefèbvre PJ
Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
[TBL] [Abstract][Full Text] [Related]
2. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
3. [Evidences demonstrating the effects of anti-atherosclerotic actions of pioglitazone--special emphasis on PROactive Study and PERISCOPE Study].
Kawamori R
Nihon Rinsho; 2010 Feb; 68(2):235-41. PubMed ID: 20158090
[TBL] [Abstract][Full Text] [Related]
4. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.
Erdmann E; Dormandy JA; Charbonnel B; Massi-Benedetti M; Moules IK; Skene AM;
J Am Coll Cardiol; 2007 May; 49(17):1772-80. PubMed ID: 17466227
[TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
Wilcox R; Kupfer S; Erdmann E;
Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
[TBL] [Abstract][Full Text] [Related]
6. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
Pfützner A; Forst T
Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
[TBL] [Abstract][Full Text] [Related]
8. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
Haberbosch W
Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
[TBL] [Abstract][Full Text] [Related]
9. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.
Erdmann E; Harding S; Lam H; Perez A
Diabetes Obes Metab; 2016 Mar; 18(3):266-73. PubMed ID: 26592506
[TBL] [Abstract][Full Text] [Related]
10. Organ protection in the secondary prevention of type 2 diabetes.
Schernthaner G
Drugs Today (Barc); 2006 Dec; 42 Suppl C():17-23. PubMed ID: 17245477
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).
Charbonnel B; DeFronzo R; Davidson J; Schmitz O; Birkeland K; Pirags V; Scheen A;
J Clin Endocrinol Metab; 2010 May; 95(5):2163-71. PubMed ID: 20237169
[TBL] [Abstract][Full Text] [Related]
12. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone.
Betteridge DJ
Fundam Clin Pharmacol; 2009 Dec; 23(6):675-9. PubMed ID: 19744248
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).
Wilcox R; Bousser MG; Betteridge DJ; Schernthaner G; Pirags V; Kupfer S; Dormandy J;
Stroke; 2007 Mar; 38(3):865-73. PubMed ID: 17290029
[TBL] [Abstract][Full Text] [Related]
14. [Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence].
Holleman F; Gerdes VE; de Vries JH; Hoekstra JB
Ned Tijdschr Geneeskd; 2006 Feb; 150(7):358-60. PubMed ID: 16523797
[TBL] [Abstract][Full Text] [Related]
15. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Barnett AH
Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).
Erdmann E; Charbonnel B; Wilcox RG; Skene AM; Massi-Benedetti M; Yates J; Tan M; Spanheimer R; Standl E; Dormandy JA;
Diabetes Care; 2007 Nov; 30(11):2773-8. PubMed ID: 17666462
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk and cardiometabolic protection: role of glitazones.
Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
[TBL] [Abstract][Full Text] [Related]
18. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.
Doehner W; Erdmann E; Cairns R; Clark AL; Dormandy JA; Ferrannini E; Anker SD
Int J Cardiol; 2012 Dec; 162(1):20-6. PubMed ID: 22037349
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
